Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard for determining the presence of liver fibrosis) and made available for clinicians to use to...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinson, Tina, Buchanan, Ryan M., Byrne, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029954/
https://www.ncbi.nlm.nih.gov/pubmed/36417894
http://dx.doi.org/10.3350/cmh.2022.0348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029954/
https://www.ncbi.nlm.nih.gov/pubmed/36417894
http://dx.doi.org/10.3350/cmh.2022.0348

Ejemplares similares